Ultragenyx Pharmaceutical (RARE) concentration risks

The company carries two distinct supply and commercialization dependencies that together define its concentration profile. The first is a broad, high-share supplier dependency: the failure to supply by any of its single-source suppliers could adversely affect the business, covering the manufacture of its investigational and commercial products. Because certain inputs have no readily available alternative source, any disruption at a single-source vendor could halt or delay production of affected products with limited near-term recourse. The second is a counterparty dependency of moderate size: the company depends on KKC for the supply and commercialization of Crysvita in certain major markets. Unlike a generic single-source supplier, KKC is a named strategic partner whose role spans both manufacturing and commercial execution in specific geographies, making the relationship more layered — its health and alignment with the company's own commercial strategy are directly load-bearing for that product's revenue in those markets. Together, the two exposures sit in different dimensions of the same supply chain and commercialization chain but reinforce a common theme: the company is reliant on a small number of external parties for both production and market access. There are no disclosed customer or geographic concentrations that compound these supplier-side risks. On balance, the supply-chain dependency is the dominant watch item, with KKC's execution in its designated markets as the most readily observable near-term indicator.

For the engine’s reasoning on RARE’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.